Virtual Screening of an FDA Approved Drugs Database on Two COVID-19 Coronavirus Proteins

13 February 2020, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

The infection by the 2019-nCoV coronavirus (COVID-19) is a world-wide emergency.
The crystal structure of a protein essential for virus replication has been filed in the Protein Data
Bank recently. Additionally, homology models of 24 COVID-19 proteins were made available by
the Zhang group. In this paper, we present results deriving from the virtual screening of a database
of more than 3000 FDA approved drugs on two distinct targets. Results showed that some of the
known protease inhibitors currently used in HIV infections might be helpful for the therapy of
COVID-19 also.

Keywords

COVID-19
coronavirus
protease
virtual screening
Nwat-MMGBSA
FDA drugs

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.